|
|
Post-surgical resection prognostic value of combined OPN, MMP7, and PSG9 plasma biomarkers in hepatocellular carcinoma |
Weiqi Rong1, Yang Zhang1, Lei Yang2, Lin Feng2, Baojun Wei3, Fan Wu1, Liming Wang1, Yanning Gao2, Shujun Cheng2, Jianxiong Wu1(), Ting Xiao2() |
1. Department of Abdominal Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China 2. State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China 3. Clinical Laboratory, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China |
|
|
Abstract Biomarkers for hepatocellular carcinoma (HCC) following curative resection are not currently sufficient for prognostic indication of overall survival (OS) and disease-free survival (DFS). The aim of this study was to investigate the prognostic performance of osteopontin (OPN), matrix metalloproteinase 7 (MMP7), and pregnancy specific glycoprotein 9 (PSG9) in patients with HCC. A total of 179 prospective patients with HCC provided plasma before hepatectomy. Plasma OPN, MMP7, and PSG9 levels were determined by enzyme-linked immunosorbent assay. Correlations between plasma levels, clinical parameters, and outcomes (OS and DFS) were overall analyzed. High OPN (≥149.97 ng/mL), MMP7 (≥2.28 ng/mL), and PSG9 (≥45.59 ng/mL) were prognostic indicators of reduced OS (P<0.001, P<0.001, and P=0.007, respectively). Plasma PSG9 protein level was an independent factor in predicting OS (P=0.008) and DFS (P=0.038). Plasma OPN+MMP7+PSG9 elevation in combination was a prognostic factor for OS (P<0.001). OPN was demonstrated to be a risk factor-associated OS in stage I patients with HCC and patients with low α-fetoprotein levels (<20 ng/mL). These findings suggested that OPN, MMP7, PSG9 and their combined panels may be useful for aiding in tumor recurrence and mortality risk prediction of patients with HCC, particularly in the early stage of HCC carcinogenesis.
|
Keywords
biomarkers
OPN
MMP7
PSG9
HCC
prognosis
|
Corresponding Author(s):
Jianxiong Wu,Ting Xiao
|
Just Accepted Date: 11 April 2018
Online First Date: 16 May 2018
Issue Date: 28 March 2019
|
|
1 |
LATorre, F Bray, RLSiegel, JFerlay, JLortet-Tieulent, AJemal. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65(2): 87–108
https://doi.org/10.3322/caac.21262
pmid: 25651787
|
2 |
TLu, WK Seto, RXZhu, CLLai, MF Yuen. Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J Gastroenterol 2013; 19(47): 8887–8894
https://doi.org/10.3748/wjg.v19.i47.8887
pmid: 24379612
|
3 |
TKumada, H Toyoda, TTada, SKiriyama, MTanikawa, YHisanaga, AKanamori, JTanaka, CKagebayashi, SSatomura. High-sensitivity Lens culinaris agglutinin-reactive α-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol 2014; 49(3): 555–563
https://doi.org/10.1007/s00535-013-0883-1
pmid: 24057163
|
4 |
AKornberg, U Witt, EMatevossian, BKüpper, VAssfalg, ADrzezga, NHüser, MWildgruber, HFriess. Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC. PLoS One 2013; 8(1): e53960
https://doi.org/10.1371/journal.pone.0053960
pmid: 23349774
|
5 |
JCheng, W Wang, CSun, MLi, B Wang, YLv. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol 2014; 48(9): 806–814
https://doi.org/10.1097/MCG.0000000000000018
pmid: 24247813
|
6 |
RTateishi, S Shiina, HYoshida, TTeratani, SObi, N Yamashiki, HYoshida, MAkamatsu, TKawabe, MOmata. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology 2006; 44(6): 1518–1527
https://doi.org/10.1002/hep.21408
pmid: 17133456
|
7 |
CLugassy, M Wadehra, XLi, MCorselli, DAkhavan, SWBinder, BPéault, AJCochran, PSMischel, HKKleinman, RLBarnhill. Pilot study on “pericytic mimicry” and potential embryonic/stem cell properties of angiotropic melanoma cells interacting with the abluminal vascular surface. Cancer Microenviron 2013; 6(1): 19–29
https://doi.org/10.1007/s12307-012-0128-5
pmid: 23275074
|
8 |
SBlank, Q Wang, MIFiel, WLuan, KW Kim, HKadri, JMandeli, SPHiotis. Assessing prognostic significance of preoperative α-fetoprotein in hepatitis B-associated hepatocellular carcinoma: normal is not the new normal. Ann Surg Oncol 2014; 21(3): 986–994
https://doi.org/10.1245/s10434-013-3357-z
pmid: 24232510
|
9 |
KShimada, Y Sakamoto, MEsaki, TKosuge, CMorizane, MIkeda, HUeno, T Okusaka, YArai, KTakayasu. Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol 2007; 14(8): 2337–2347
https://doi.org/10.1245/s10434-007-9415-7
pmid: 17503155
|
10 |
JAMarrero, Z Feng, YWang, MHNguyen, ASBefeler, LRRoberts, KRReddy, DHarnois, JMLlovet, DNormolle, JDalhgren, DChia, AS Lok, PDWagner, SSrivastava, MSchwartz. α-fetoprotein, des-γ carboxyprothrombin, and lectin-bound α-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137(1): 110–118
https://doi.org/10.1053/j.gastro.2009.04.005
pmid: 19362088
|
11 |
SJFu, CY Qi, WKXiao, SQLi, BG Peng, LJLiang. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. Surgery 2013; 154(3): 536–544
https://doi.org/10.1016/j.surg.2013.02.014
pmid: 23601901
|
12 |
YMao, H Yang, HXu, XLu, X Sang, SDu, HZhao, W Chen, YXu, TChi, Z Yang, JCai, HLi, J Chen, SZhong, SRMohanti, RLopez-Soler, JMMillis, JHuang, HZhang. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010; 59(12): 1687–1693
https://doi.org/10.1136/gut.2010.214916
pmid: 20876776
|
13 |
MKobayashi, T Hosaka, KIkeda, YSeko, Y Kawamura, HSezaki, NAkuta, FSuzuki, YSuzuki, SSaitoh, YArase, HKumada. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res 2011; 41(11): 1036–1045
https://doi.org/10.1111/j.1872-034X.2011.00858.x
pmid: 21883741
|
14 |
JLiu, K Xu, MChase, YJi, JK Logan, RJBuchsbaum. Tiam1-regulated osteopontin in senescent fibroblasts contributes to the migration and invasion of associated epithelial cells. J Cell Sci 2012; 125(Pt 2): 376–386
https://doi.org/10.1242/jcs.089466
pmid: 22302986
|
15 |
WKSyn, KM Agboola, MSwiderska, GAMichelotti, ELiaskou, HPang, G Xie, GPhilips, ISChan, GFKaraca, TAPereira, YChen, Z Mi, PCKuo, SSChoi, CDGuy, MF Abdelmalek, AMDiehl. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease. Gut 2012; 61(9): 1323–1329
https://doi.org/10.1136/gutjnl-2011-301857
pmid: 22427237
|
16 |
JSun, HM Xu, HJZhou, QZDong, YZhao, LY Fu, ZYHei, QHYe, N Ren, HLJia, LXQin. The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol 2010; 136(1): 1–7
https://doi.org/10.1007/s00432-009-0629-x
pmid: 19593583
|
17 |
SShang, A Plymoth, SGe, ZFeng, HR Rosen, SSangrajrang, PHainaut, JAMarrero, LBeretta. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012; 55(2): 483–490
https://doi.org/10.1002/hep.24703
pmid: 21953299
|
18 |
SPhilip, GC Kundu. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through IκBα/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 2003; 278(16): 14487–14497
https://doi.org/10.1074/jbc.M207309200
pmid: 12473670
|
19 |
TXiao, W Ying, LLi, ZHu, Y Ma, LJiao, JMa, Y Cai, DLin, SGuo, N Han, XDi, MLi, D Zhang, KSu, JYuan, H Zheng, MGao, JHe, S Shi, WLi, NXu, H Zhang, YLiu, KZhang, YGao, X Qian, SCheng. An approach to studying lung cancer-related proteins in human blood. Mol Cell Proteomics 2005; 4(10): 1480–1486
https://doi.org/10.1074/mcp.M500055-MCP200
pmid: 15970581
|
20 |
LYang, W Rong, TXiao, YZhang, BXu, Y Liu, LWang, FWu, J Qi, XZhao, HWang, N Han, SGuo, JWu, Y Gao, SCheng. Secretory/releasing proteome-based identification of plasma biomarkers in HBV-associated hepatocellular carcinoma. Sci China Life Sci 2013; 56(7): 638–646
https://doi.org/10.1007/s11427-013-4497-x
pmid: 23749381
|
21 |
YZhang, B Xu, YLiu, HYao, N Lu, BLi, JGao, S Guo, NHan, JQi, K Zhang, SCheng, HWang, X Zhang, TXiao, LWu, Y Gao. The ovarian cancer-derived secretory/releasing proteome: a repertoire of tumor markers. Proteomics 2012; 12(11): 1883–1891
https://doi.org/10.1002/pmic.201100654
pmid: 22623176
|
22 |
JBruix, M Sherman; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53(3): 1020–1022
https://doi.org/10.1002/hep.24199
pmid: 21374666
|
23 |
SBEdge, CC Compton. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17(6):1471–1474
|
24 |
QShen, J Fan, XRYang, YTan, W Zhao, YXu, NWang, Y Niu, ZWu, JZhou, SJ Qiu, YHShi, BYu, N Tang, WChu, MWang, J Wu, ZZhang, SYang, J Gu, HWang, WQin. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 2012; 13(8): 817–826
https://doi.org/10.1016/S1470-2045(12)70233-4
pmid: 22738799
|
25 |
JLambert, S Chevret. Summary measure of discrimination in survival models based on cumulative/dynamic time-dependent ROC curves. Stat Methods Med Res 2016; 25(5): 2088–2102
pmid: 24395866
|
26 |
WZhu, L Guo, BZhang, LLou, Z Lin, XZhu, NRen, Q Dong, QYe, LQin. Combination of osteopontin with peritumoral infiltrating macrophages is associated with poor prognosis of early-stage hepatocellular carcinoma after curative resection. Ann Surg Oncol 2014; 21(4): 1304–1313
https://doi.org/10.1245/s10434-013-3445-0
pmid: 24366422
|
27 |
WSieghart, X Wang, KSchmid, MPinter, FKönig, MBodingbauer, FWrba, S Rasoul-Rockenschaub, MPeck-Radosavljevic. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol 2011; 54(1): 89–97
https://doi.org/10.1016/j.jhep.2010.06.030
pmid: 20970216
|
28 |
HZhang, QH Ye, NRen, LZhao, YF Wang, XWu, HCSun, L Wang, BHZhang, YKLiu, ZY Tang, LXQin. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2006; 132(11): 709–717
https://doi.org/10.1007/s00432-006-0119-3
pmid: 16786357
|
29 |
RXChen, YH Xia, JFCui, TCXue, SL Ye. Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection. J Gastroenterol Hepatol 2010; 25(8): 1435–1442
https://doi.org/10.1111/j.1440-1746.2010.06277.x
pmid: 20659235
|
30 |
MWang, A Mehta, TMBlock, JMarrero, AMDi Bisceglie, KDevarajan. A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables. BMC Med Genomics 2013; 6 (Suppl 3):S9
https://doi.org/10.1186/1755-8794-6-S3-S9
pmid: 24564861
|
31 |
YIshii, Y Nakasato, SKobayashi, YYamazaki, TAoki. A study on angiogenesis-related matrix metalloproteinase networks in primary hepatocellular carcinoma. J Exp Clin Cancer Res 2003; 22(3): 461–470
pmid: 14582707
|
32 |
KKessenbrock, V Plaks, ZWerb. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141(1): 52–67
https://doi.org/10.1016/j.cell.2010.03.015
pmid: 20371345
|
33 |
BLiang, R Chen, TWang, LCao, Y Liu, FYin, MZhu, X Fan, YLiang, LZhang, YGuo, J Zhao. Myeloid differentiation factor 88 promotes growth and metastasis of human hepatocellular carcinoma. Clin Cancer Res 2013; 19(11): 2905–2916
https://doi.org/10.1158/1078-0432.CCR-12-1245
pmid: 23549880
|
34 |
TMHung, SC Chang, WHYu, YWWang, CHuang, SCLu, PH Lee, MFChang. A novel nonsynonymous variant of matrix metalloproteinase-7 confers risk of liver cirrhosis. Hepatology 2009; 50(4): 1184–1193
https://doi.org/10.1002/hep.23137
pmid: 19676133
|
35 |
SSalahshor, J Goncalves, RChetty, SGallinger, JRWoodgett. Differential gene expression profile reveals deregulation of pregnancy specific β1 glycoprotein 9 early during colorectal carcinogenesis. BMC Cancer 2005; 5:66
https://doi.org/10.1186/1471-2407-5-66
pmid: 15982419
|
36 |
FALisboa, J Warren, GSulkowski, MAparicio, GDavid, EZudaire, GSDveksler. Pregnancy-specific glycoprotein 1 induces endothelial tubulogenesis through interaction with cell surface proteoglycans. J Biol Chem 2011; 286(9): 7577–7586
https://doi.org/10.1074/jbc.M110.161810
pmid: 21193412
|
37 |
LXQin, ZY Tang. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004; 130(9): 497–513
https://doi.org/10.1007/s00432-004-0572-9
pmid: 15205947
|
38 |
AOsaki, T Suda, KKamimura, ATsuchiya, YTamura, MTakamura, MIgarashi, HKawai, SYamagiwa, YAoyagi. A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Med 2013; 2(1): 86–98
https://doi.org/10.1002/cam4.55
pmid: 24133631
|
39 |
MSherman. Recurrence of hepatocellular carcinoma. N Engl J Med 2008; 359(19): 2045–2047
https://doi.org/10.1056/NEJMe0807581
pmid: 18923166
|
40 |
JCWu, YH Huang, GYChau, CWSu, CR Lai, PCLee, TIHuo, IJ Sheen, SDLee, WYLui. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009; 51(5): 890–897
https://doi.org/10.1016/j.jhep.2009.07.009
pmid: 19747749
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|